Drug Type Antibody drug conjugate (ADC) |
Synonyms TGW101 |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors, Tumor-associated glycoprotein 72 inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 07 May 2025 | |
Solid tumor | Preclinical | Netherlands | 01 Nov 2024 |